Dario Healtha digital chronic disease management platform, announced it will integrate Twill’s disease-specific communities and peer groups with customized navigation expertise into its cardiometabolic platform.
DarioHealth Acquires Digital Therapeutics Company It founded Twill in February with a $22.4 million equity raise.
The combination will expand Dalio’s holistic approach to managing chronic conditions, including diabetes, hypertension and weight management, with the goal of increasing member engagement and improving health outcomes.
The enhanced features will allow Dario members to join peer-to-peer medical condition groups, engage with medical experts for advice, and access customized educational content.
“There is no single standard of care for all chronic health conditions that applies to the diverse membership on the Dalio platform,” Dalio chief product officer Keren Zimmerman said in a statement.
“That’s why we’re constantly evaluating clinical evidence and behavioral engagement data to continually enhance how we support our members, and our new enhancements provide the elements many need to achieve better outcomes.”
___________________________________________________________________________________
Nordic pharmaceutical company Navamedic Alex Therapeutics, a digital health provider with a disease-and-medication companion app to help manage Parkinson’s treatment;
Alex Therapeutics’ app supports patients taking Flexilev (levodopa/carbidopa mini-tablets), a prescription drug for the treatment of Parkinson’s disease.
The company says the app provides medication management support focused on the needs and challenges of Parkinson’s patients and complements its medication dispensers, including Flexilev, OraFID (a mini pill dispenser).
“We are pleased to be working with Alex Therapeutics to improve the lives of people with Parkinson’s disease through our companion app,” Navamedic CEO Katherine Gunborg Andreasen said in a statement.
“This partnership not only reflects our efforts to make care more accessible and manageable, but also underscores our dedication to reducing the burden patients face in their day-to-day care.”
___________________________________________________________________________________
Mobile Health Consumer, a digital health and wellbeing solutions provider, has announced the launch of two programs: the GLP-1 Prerequisite Program and the GLP-1 Lifestyle Support Program. Both programs aim to foster healthier lifestyle habits before, during and after medication use.
GLP-1 is a type of drug used to treat type 2 diabetes and obesity.
Mobile Health’s programs provide comprehensive support aimed at increasing the effectiveness of medications with the goal of reducing long-term healthcare costs.
The first program is a digital GLP-1 prerequisite program, building a foundation for success and equipping employees with knowledge on nutrition, physical activity and sustainable lifestyle changes before starting GLP-1 medication.
Employees can also integrate wearable devices, Bluetooth scales, activity trackers and health data into the program, which also provides customized weight management, nutrition and fitness education and mental health support.
The second is Digital GLP-1 Life Support. The program provides employees with tools during and after GLP-1 treatment and emphasizes the importance of lasting lifestyle changes.
Employees can also integrate wearable devices, Bluetooth scales, activity trackers and health data into the program.
“GLP-1 drugs offer a powerful tool in the fight against obesity and related chronic diseases, but true success cannot be achieved with drugs alone,” John Halloran, CEO of Mobile Health Consumer, said in a statement.
“Our program not only prepares employees for GLP-1 treatment with proper weight management and lifestyle education, but also helps them maintain healthy habits long after they stop taking the medication.”
